BPC-157

The entire published human record for BPC-157 is three uncontrolled pilot studies, about thirty people between them, no control group in any of them, and the same physician as first author on all three. A fourth human trial existed: a randomised, placebo-controlled study in ulcerative colitis run by a pharmaceutical company as PL-14736, described inside a 2012 review and never published as a standalone paper, so no independent researcher has been able to read it ¹². Everything else people quote at each other is animal research, and there is a great deal of it. A 2025 systematic review in HSS Journal screened 544 papers published between 1993 and 2024 and included 36, of which 35 were preclinical and one was clinical ¹. BPC-157 itself is a lab-made chain of 15 amino acids copied from a protein reported in human stomach fluid.

What BPC-157 is

BPC-157 is a pentadecapeptide, meaning a chain of exactly 15 amino acids. It is a partial sequence attributed to a larger protein called body protection compound, reported in human gastric juice, the acidic fluid the stomach makes ¹¹. That origin is why the gut is its oldest use case and why the oral form exists at all: a molecule described as coming out of stomach fluid is built to survive stomach fluid. It is worth knowing that the parent protein's characterisation rests on the same single research lineage that produced most of the animal work.

The compound sold today is synthesised in a laboratory rather than extracted from anyone. It carries several names in the literature. Papers from the Zagreb group that produced most of the animal research call it stable gastric pentadecapeptide BPC 157. The Croatian pharmaceutical company Pliva, which took it into clinical development for inflammatory bowel disease, called it PL-14736. Vendors call it BPC-157, and pair it with a salt form (acetate or arginine) that changes how it dissolves and stores, not what it is.

BPC-157 is derived from a human protein and BPC-157 is a normal part of human biology are different claims, and only the first is supported. Nobody has shown that the 15-amino-acid fragment circulates in people at measurable levels. It is a synthetic molecule with a human ancestor.

Does BPC-157 work, and how would we know?

For soft-tissue injury in rats, the animal evidence says yes, repeatedly and across separate injury models. For humans, nobody can answer the question yet, because the studies that exist could not have detected the difference between a working compound and an injury that was going to improve anyway. Here is the entire published human record on one screen.

That table is the reason to be careful with any confident claim about BPC-157, in either direction. An uncontrolled study cannot separate the treatment from time, from rest, from the placebo response, or from the fact that people who feel better are the ones who answer the follow-up call. The interstitial cystitis result in particular, where 10 of 12 women rated their outcome at 100% after a single procedure, is the shape of result that most often shrinks when a placebo arm is added, because the comparison procedure also involves a specialist, a camera inspection of the bladder and an expectation of relief.

Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution.McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM, Current Reviews in Musculoskeletal Medicine, 2025 [[2]]

The 2025 HSS Journal review is blunter still on safety than on efficacy. Its conclusion has two halves: preclinical safety studies showed no adverse effects across several organ systems, and no clinical safety data were found ¹. Both halves matter, and most coverage quotes only the first.

Peptide BPC-157: Does It Work? Breaking Down the Evidence and the HypeTalking With Docs · plays on YouTube

What the animal research measured, tissue by tissue

The preclinical literature is not one big study, it is dozens of small ones across different injuries. The useful question for each is what was measured, in what, and how far it is from a person. Each condition below has its own page on this site that goes deeper into the injury itself.

What happens after an injection, and on what timeline

The mechanism is where the animal literature is most coherent, and it is more specific than the usual description of a repair peptide. BPC-157 is not adding a new instruction to heal. It is improving the delivery of the ones your body is already sending, into tissue that has a bad blood supply to begin with. Tendons and ligaments heal slowly for exactly that reason.

The pharmacokinetics, meaning what the body does to the compound rather than the reverse, are known in animals only. The only published study gave BPC-157 to rats and beagle dogs by vein and by muscle, and found an elimination half-life under 30 minutes across routes and doses, with absolute bioavailability from an intramuscular injection of roughly 14% to 19% in rats and 45% to 51% in dogs ³. Bioavailability means the share of an injected dose that actually reaches the bloodstream, so most of a rat's intramuscular dose never got there. The same study found the peptide broken down into small fragments and then into single amino acids, and cleared in urine and bile. No human pharmacokinetic data has ever been published, and no published study measured the subcutaneous route in any species, which is the route almost everyone uses and the one the new trial uses.

That is also why no reliable healing timeline exists. The week-by-week schedules circulating online are read off animal healing models, where a rat Achilles tendon is cut and then examined at four weeks, not off measured human recovery. The one trial designed to produce a human timeline, NCT07437547, measures MRI injury volume at day 14 and time back to full sport, with primary results estimated for February 2027 ¹⁰. Dosing detail, including what research protocols used, lives on the BPC-157 dosage guide, and the most common errors people make with any peptide are collected in peptide dosing mistakes.

Is oral BPC-157 effective?

Oral BPC-157 rests on one real finding and one unmeasured assumption, and the difference between them is the whole answer. The real finding is gastric stability: BPC-157 is described as stable in human gastric juice for more than 24 hours, which is extraordinary for a peptide, most of which are taken apart within a couple of hours ¹¹. The unmeasured assumption is that surviving the stomach means crossing the gut wall into the bloodstream. Those are separate questions, and the second one has never been answered in a person.

Vendors sell an arginine-salt oral form and quote high absorption figures for it against the more common acetate form. Salt form genuinely changes how a peptide dissolves and stores. It has not been shown to change human absorption of BPC-157, because human absorption of BPC-157 has never been measured in any form. Treat a specific oral bioavailability percentage from a seller as a marketing number until a paper carries it.

The doses the research used

These are reported research protocols, not instructions, and several are in animals where the dose is scaled by body weight in a way that does not transfer to a person. They are the concrete numbers behind claims that usually arrive without any.

What people use it for, and what the evidence says for each

Tendons and ligaments

This is the most common reason someone lands on this page, and it is where the animal work is thickest. The mechanism fits the tissue: tendons heal slowly because blood struggles to reach them, and improving blood supply is the thing BPC-157 is best documented as doing. The cell-level effect is the one described in the mechanism section above, survival and migration rather than multiplication ⁵, and in rat Achilles models treated animals show better collagen organisation, with the one cited biomechanical comparison finding a strength improvement that did not reach statistical significance ⁸.

The most useful recent study is also the least flattering. A 2026 rat Achilles experiment randomised 32 animals into four groups (control, BPC-157 at 10 mcg/kg per day, TB-500 at 60 mcg/kg per day, and both together) for four weeks after a surgical repair. Both peptides improved tissue appearance under the microscope, but only the TB-500 group reached statistical significance on maximum load to failure, the measure of how much force the repaired tendon could take before it broke. The BPC-157 group improved without reaching significance, and combining the two conferred no additional benefit over either alone ⁸. One 32-rat study does not settle anything, but it is the only head-to-head comparison that exists, and it does not support the common assumption that the pair beats either one.

The full pairing question, including how the two compounds' very different half-lives change how people schedule them, belongs to TB-500 and BPC-157 half-life compared, which puts the core point this way: TB-500 clears the blood in 1.5 to 3 hours but binds into tissue for 3 to 5 days, while BPC-157 is gone from blood in minutes. For the injury itself, see peptides for tendonitis.

The gut

The gut is BPC-157's oldest use case and the reason it exists, since the parent protein was reported in stomach fluid ¹¹. The rat literature here goes back to the 1990s and covers damage from anti-inflammatory painkillers, ulcers, reflux after stomach surgery, and the strength of surgical joins in the bowel. It is also the only area where BPC-157 reached a proper randomised human trial, run by Pliva as PL-14736 in ulcerative colitis. That trial's results were described inside a 2012 review as dose-dependent improvement and were never published as a standalone paper ¹², which means no outside researcher has ever been able to check them. An unpublished positive result is not evidence, and a company deciding not to publish is information in itself.

The practical point people take from the gut research is the oral route, since a compound that survives gastric juice can reach the gut lining without needing to reach the bloodstream first. The condition context, including what else is used for barrier problems, sits on peptides for gut healing.

Can BPC-157 Fix Your Gut and Joints?Dr. Jin W. Sung · plays on YouTube

Brain and head injury

There is a real animal literature here, mostly from the same Zagreb group, covering impact injury, interrupted blood flow to the brain, and spinal cord injury, and reporting less swelling and better preserved function in treated animals. There is no human data of any kind.

Joints

The knee series is the only published human efficacy signal BPC-157 has, and what it was matters. A clinic reviewed a year of charts, phoned 16 patients who had received an injection into the knee 6 to 12 months earlier, and asked them to rate their pain before and after. 14 of 16 reported relief ⁶. Nobody received a placebo injection, nobody was blinded, no imaging was repeated, and the patients who could not be reached were not counted. That is a reason to run a trial, not a result. For the joint context itself see peptides for joint pain and, for the inflammatory side, peptides for inflammation.

What people combine it with, and how those compounds compare

Does BPC-157 have side effects?

Nobody has run the kind of study that could answer this properly. The 2025 systematic review's conclusion on the point is that preclinical safety studies showed no adverse effects across several organ systems, and that no clinical safety data were found ¹. Because BPC-157 is not an approved medicine, there is also no system routinely collecting reports when something does go wrong, so absence of reports is close to meaningless.

What people who use it describe is mild and mostly local, and the tolerability table further down this page sets it out. What no table can supply is a denominator: none of those reports come from a study that counted how many people took the compound, so they say what happens to somebody without saying how often. Carcinogenicity has never been studied, pregnancy and breastfeeding exposure has never been studied, and no drug-interaction study of any kind exists.

Storage, stability and what it costs

Vendors and research suppliers describe the following handling. BPC-157 ships as a freeze-dried white powder in a sealed vial, stable at room temperature for shipping but normally kept refrigerated and out of light. As how to reconstitute peptides puts it: "Lyophilized BPC-157 stored correctly has a shelf life of 24 to 36 months. The same peptide reconstituted and kept at 4 degrees C is good for two to four weeks." Bacteriostatic water, the sterile water containing a preservative that is used to mix it, is the usual diluent, which is why vial size and mixing volume are practical decisions rather than trivia. The research-chemical vendors on our vendor comparison page listed BPC-157 vials in the region of $40 as of August 2026, at the cheap end of the peptide market and part of why it spread so quickly. Those are research-chemical listings, labelled for laboratory use rather than human use, and the price reflects that: at $40 a vial, nobody is paying for the testing that would tell you what is in it.

Why two people report completely different results

Before genetics, five ordinary explanations account for most of the variation, and each is more likely than any gene.

• Amount. What people use varies enormously, and no dose-finding trial exists to anchor it.
• Placement. Where it is injected relative to the injury differs from person to person, and no study has tested near against far head to head.
• Tissue. A compound whose main documented effect is improving blood supply has more to offer a poorly supplied tendon than a well-supplied muscle.
• Time. Tendon remodelling runs over months, and most people judge the result in weeks.
• Product quality. A large share of grey-market vials fail basic purity and endotoxin testing ¹³, which alone can account for two people having opposite experiences of the same label.

There is one mechanistic reason genetics could plausibly matter, and it is so often overstated that it needs stating precisely. BPC-157's effect on blood vessels is nitric-oxide dependent: in isolated rat aorta, blocking the enzyme that makes nitric oxide, or removing the nitric oxide with haemoglobin, abolished the widening entirely ⁴. NOS3 is the gene that builds that enzyme in the lining of blood vessels, and people carry different versions of it, with the common Glu298Asp version (also written G894T, rs1799983) among the variants studied for their effect on how much nitric oxide the enzyme produces ¹⁶. Nobody has checked whether NOS3 genotype changes BPC-157 response in any species, so what you gain is one specific thing to ask a clinician: if my nitric-oxide gene version is the lower-output one, does that change what we would expect from a compound whose main documented effect depends on nitric oxide? Nobody can answer that yet, and a page that told you it could would be selling you something.

The other two variants on this page are there for a different reason again. One shapes the collagen a repair is built from, the other helps clear damaged tissue out before new tissue goes in, and both have been studied for who tends to tear a tendon in the first place. Neither has ever been tested against BPC-157, in people or in animals. Susceptibility markers and response markers are different things, and this page will not pretend otherwise. What your report can tell you is which versions you carry; what it cannot tell you is whether this compound will work for you.

Is BPC-157 legal in the US in 2026?

It has never been approved as a medicine for human use in the United States or anywhere else, and the compounding position moved twice in 2026 without changing that.

1. 1September 2023: placed in Category 2Compounding pharmacies mix medicines to order from bulk ingredients. The FDA put BPC-157 into Category 2 of its review of those bulk substances, the list of substances that may present significant safety risks, which barred pharmacies from using it [[14]].
2. 222 April 2026: removed from Category 2It came off that list after the nominations behind it were withdrawn. It was not moved to Category 1, the list of substances pharmacies may use. From that date the compound sat on neither list, which left compounding pharmacies with no route to use it [[14]].
3. 323 July 2026: an advisory committee voted 8 to 6The FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding BPC-157 (and KPV) to the 503A bulks list, the register of raw ingredients compounding pharmacies are allowed to make medicines from [[17]]. It voted that way against the position of the FDA's own reviewers, who found no human injectable trial data [[15]]. The vote is advisory and non-binding.
4. 4Today: still not approved, still not compoundableChanging the bulks list requires formal rulemaking, which takes months to years and has not happened. BPC-157 remains an unapproved substance, sold widely as a research chemical, which is a different thing from being legal to take. Status checked August 2026, and this list has moved twice in two years, so check the current FDA 503A bulks list before relying on anything here [[14]].

The wider picture for peptides generally, including what research-chemical labelling means and what personal importation risks, is covered in are peptides legal in the US in 2026, which sums the compounding position up in six words: "Your pharmacy still cannot legally make it."

What would change the picture

One trial would settle most of this. NCT07437547 is randomised, placebo-controlled and quadruple-masked, meaning participants, treating clinicians, investigators and outcome assessors are all blinded. It is recruiting 120 people with an MRI-confirmed grade II hamstring strain, assigned 1 to 1 to a daily injection under the skin or matched placebo for 14 days on top of the same rehabilitation programme, and it will judge success on how long until people return to full sport and how much the injury has shrunk on MRI at day 14. Primary completion is estimated for February 2027, with full study completion in February 2028 ¹⁰. It is the first study in BPC-157's history capable of producing an answer rather than an impression.

Here is what a result would need to contain to move this page from investigational to useful:

• A difference from placebo on a measurement nobody can talk themselves into, which is why MRI-measured injury volume matters more than a pain score.
• A side-effect rate with a denominator, so that 'well tolerated' stops meaning 'nobody was counting'.
• Some sense of dose and response, since not one published study has compared two doses of BPC-157 in a person.
• Replication outside the group that produced most of the animal work, which is the standard any compound with a single dominant research lineage has to meet.
• A published human absorption figure, ideally for both the injected and the oral form, so that the oral question stops being an argument about plausibility.

Until then, the position that survives contact with the evidence is narrow: consistent animal results in one specific direction, a mechanism that makes sense for the tissues people use it on, no proof that any of it happens in a person, and no approval anywhere. If you are comparing repair compounds on evidence quality rather than reputation, the best peptides for healing ranks them side by side.

Affiliate disclosure: the vendor links below and on our vendor comparison page are affiliate links, and we may earn a commission if you buy through them. That does not change the price you pay, and it has not changed a word of the evidence above. BPC-157 is not approved for human use, and nothing on this page is a recommendation to buy or use it.

The PeptidesDNA report is an educational analysis of genetic variants described in published research. It is not a diagnostic test, it does not tell you whether any compound is safe or suitable for you, and it is not a recommendation to obtain or use any compound. It has not been reviewed by the FDA. Nothing on this page is medical advice; talk to a clinician who knows your history.